Mv. Aguilar et al., Cerebrospinal fluid selenium and chromium levels in patients with Parkinson's disease, J NEURAL TR, 105(10-12), 1998, pp. 1245-1251
We compared CSF and serum levels of selenium and chromium, measured by atom
ic absorption spectrophotometry, in 28 patients with Parkinson's disease (P
D) and 43 matched controls. The CSF and serum levels of these trace metals
did not differ significantly between PD patients and controls. CSF selenium
and chromium levels were not correlated with age, age at onset? duration o
f the disease, scores of the Unified Parkinson Disease Rating Scale of the
Hoehn and Yahr staging in the PD group. Although antiparkinsonian therapy d
id not influence significantly the CSF levels of selenium, PD patients not
treated with levodopa had significantly higher CSF selenium levels than con
trols (p < 0.01). It is possible that increased CSF selenium levels could i
ndicate an attempt of protection against oxidative stress. The normality of
CSF and serum chromium levels suggest that these values are not related wi
th the risk for PD.